Dual-Agonist Peptides: GLP-1 and GIP in Research
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
Dual-agonist peptides that engage both GLP-1 and GIP receptors are a major focus of current metabolic research. This overview explains the mechanism and research context. All information is for laboratory and educational research only. These compounds are not approved for human or veterinary use, and nothing here is medical advice.
What a dual agonist is
A dual agonist activates two receptor pathways at once · here, GLP-1 and GIP. Tirzepatide is the most-studied example; review literature characterizes it as a dual GIP/GLP-1 co-agonist [2], and the SURPASS-1 trial reported dose-dependent metabolic effects versus placebo [1]. Engaging two pathways has, in the literature, generally been associated with broader metabolic effects than single agonists in study models.
How it compares to triple agonists
Triple agonists such as retatrutide add glucagon-receptor activity. For a side-by-side, see our retatrutide vs tirzepatide vs semaglutide comparison.
Selected research references
- [1] Rosenstock J, et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-1). Lancet. doi:10.1016/S0140-6736(21)01324-6
- [2] Nauck MA, D'Alessio DA (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist. Cardiovasc Diabetol. doi:10.1186/s12933-022-01604-7
Reference metadata sourced via PubMed.
Explore metabolic research compounds in our BURN collection. Join the research list for 10% off your first order with code RESEARCH10.
Disclaimer: All products and information provided by BioRegen are for laboratory and educational research purposes only. Nothing here is medical advice, and none of these compounds are approved for human or veterinary use.